NYSE$ATR

AptarGroup Inc. · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

AptarGroup reported strong Q4 2023 operational results, driven by double-digit growth in proprietary drug delivery systems and strong growth in fragrance dispensing technologies.

AptarGroup's Q4 2023 results showed a 5% increase in reported sales and a 2% increase in core sales. Net income increased by 6% to $62 million. Adjusted earnings per share increased 27% to $1.21. The Pharma segment experienced over 20% core sales growth in proprietary dosing and dispensing systems.

  • Reported sales increased 5% and net income increased 6% to $62 million.
  • Core sales increased 2% and adjusted EBITDA increased 22% from the prior year to $179 million.
  • Reported earnings per share increased about 4% to $0.93 compared to $0.89 in the prior year, and adjusted earnings per share increased 27% to $1.21 compared to $0.95 in the prior year.
  • Margins continued to expand across all three segments over the prior year.

Headline financials

Total Revenue

$838M

Previous: $796M+5.3%
EPS (adj)

$1.21

Previous: $0.92+31.5%
Total Core Sales Growth

2.0%

Previous: 4.0%-50.0%
Pharma Core Sales Growth

11.0%

Previous: 8.0%+37.5%
Beauty Core Sales Growth

-6.0%

Previous: 2.0%-400.0%
Closures Core Sales Growth

-4.0%

Previous: -4.0%+0.0%
Capital Expenditures

$81.1M

Previous: $84.3M-3.7%
Net Income

$62.2M

Previous: $59.4M+4.8%
Operating Income

$84.2M

Previous: $85.2M-1.2%
Gross Profit

$312M

Previous: $276M+13.3%
Stock-Based Comp

$5.21M

Previous: $9M-42.1%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$838M

Q4 2023+5.3%vs Q4 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

AptarGroup · $893M total across 3 segments · Q3 2023

  • Pharma
    $389M+13.3%
  • Beauty
    $324M-10.0%
  • Closures
    $180M+34.6%

Forward guidance

Aptar expects earnings per share for Q1 2024, excluding restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.10 to $1.18.

Tailwinds

  • Demand for pharma’s proprietary drug delivery systems and elastomeric components for biologics to continue to grow.
  • Beauty and closures segments to benefit from a progressive recovery of the North American market.
  • Continued demand for fragrance dispensing technologies.
  • Remain focused on reducing SG&A as a percentage of sales.
  • Reducing fixed costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro